David Hellerstein on COMPASS’s Phase IIb trial: Psilocybin Therapy for TRD

Описание к видео David Hellerstein on COMPASS’s Phase IIb trial: Psilocybin Therapy for TRD

Professor David Hellerstein is a Professor of Clinical Psychiatry and Principal Investigator on COMPASS Pathways’ trial site at Columbia University, New York. He talks about the positive results of our phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression.

https://compasspathways.com/

Комментарии

Информация по комментариям в разработке